🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches

RecruitingPhase 3Ages 18 Years - 75 YearsAllUniversity Health Network, Toronto
NCT05306899 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Chronic daily headaches (CDH) poses a significant burden on patients, healthcare systems and the society. Intravenous (IV) ketamine infusion, an intervention that is widely available and scalable, can treat CDH by reversing receptor-mediated sensitization. This study is a multicenter, placebo-controlled, parallel group randomized trial with blinding of participants and observers with the goal of comprehensively assessing the effect of high-dose IV ketamine infusion (1 mg.kg-1.h-1 for six hours) on the frequency and intensity of headaches, mood, activity, sleep, quality of life and safety of ketamine for three months after the interventions. Use of validated questionnaires, wearable technology, a research team that includes investigators with expertise in studying ketamine and in evaluating treatments for CDH and pain syndromes are some of the unique features of this project. Our study a

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age 18-75 years 2. CDH diagnosis preceding trial enrollment with headache episodes lasting for 4 or more hours occurring on 15 or more days in a month for 3 or more months (International Headache Society-IHS criteria) 3. Normal liver and kidney function tests Exclusion criteria: 1. Pregnant or breastfeeding patients 2. Pre-existing renal impairment 3. Pre-existing liver impairment 4. Chronic benzodiazepine or antipsychotic medication use 5. History of cerebrovascular event 6. Significant and untreated hypertension or severe cardiac condition 7. Hypothyroidism 8. Glaucoma 9. Concomitant use of strong CYP2B6 or CYP2C8 inhibitor 10. Allergy or intolerance to ketamine 11. Pheochromocytoma 12. Any significant cognitive or language barriers that impede participation 13. CGRP antagonist use in 1 month or Onabotulinum-toxin A 3 months before infusion 14. Active diagnosis of Post-Traumatic Stress Disorder (PTSD) 15. Active diagnosis of Substance Use Disorder 16. Patients taking opioid medications with daily Oral Morphine Equivalents ≥80 mg
💊

What it tests

  • Ketamine
  • 0.9% Saline
📍

Where

2 sites
Women's College Hospital
Toronto, Canada
Toronto Western Hospital
Toronto, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy